The real bottleneck in pharma data work
Spend a week with a drug development team and you will see the same pattern everywhere. There are capable biostatisticians who know exactly which models to run. There are data managers who know where the data lives. And there is a gap in the middle: translating clean trial data into the analysis-ready datasets that the statisticians need, and then translating statistical outputs into the formatted documents that regulatory affairs needs.
That gap is not a biostatistics problem. It is a data engineering and systems problem. And it is exactly what most pharma teams struggle to fill with internal resources.
Four things R&D teams consistently need
Based on working with pharma, biotech, and cosmetics R&D teams, the requests cluster around four categories:
- Analysis dataset construction: building ADaM or analysis-ready datasets from raw EDC exports, applying the derivations specified in the SAP, with a documented and reproducible pipeline.
- Automated reporting: replacing manual copy-paste report assembly with Quarto or R Markdown documents that regenerate from locked data with one command.
- Interactive exploration tools: Shiny applications that let non-technical team members (medical, regulatory, commercial) interrogate the data without needing to write code.
- CDISC mapping: building SDTM or ADaM domains from sponsor-defined data structures, often for first submissions at small biotechs with no existing CDISC infrastructure.
The GxP translation problem
The most underestimated skill in pharma data work is understanding GxP constraints well enough to make practical decisions about them. What version control system satisfies 21 CFR Part 11 for your specific use case? Which renv configuration is sufficient for a Phase II analysis dataset? Does your Shiny app need to be validated, and if so, to what level?
A general-purpose data scientist without pharma experience will spend weeks asking these questions to regulatory affairs before writing a line of code. A specialist who has worked in this environment knows which questions to ask and which can be resolved with a practical judgment call.
Why delivery speed matters more than sophistication
Drug development timelines are unforgiving. The clinical team needs the interim analysis by Monday to decide whether to continue the trial. The regulatory submission window is fixed. In this environment, a good-enough analysis delivered on time is more valuable than a perfect analysis delivered late.
This has implications for what you should look for in a freelance data specialist: someone who can scope a realistic deliverable, communicate early when the scope needs to change, and deliver working code that does not require extensive post-delivery cleanup.
The collaboration model that works
The most effective collaboration model I have seen in pharma R&D engagements has three elements:
- Clear scope with a written brief: exactly what dataset, what analysis, what output format, by when. Vague scope creates surprises late in the project.
- Access to the right people early: one meeting with the statistician who wrote the SAP before writing any code saves more time than any amount of solo work.
- Incremental delivery: weekly check-ins with a working draft rather than a big reveal at the end. Regulatory context often means the first version will need to change once it is seen by someone who understands the submission requirements.
What to look for in a freelance data specialist
When evaluating a freelance data specialist for pharma or biotech work, the questions that matter most are not about machine learning or cloud infrastructure. They are:
- Have you delivered analysis-ready datasets for a regulatory submission?
- Can you implement a CDISC domain from scratch in R?
- How do you handle a situation where the analysis deviates from the SAP?
- How do you version-control analysis code, and what does your audit trail look like?
- Can you show me an example of automated reporting output?
Questions to ask before engaging
Before signing an engagement, clarify:
- What is the regulatory context? Phase I/II/III, EMA or FDA submission, or internal R&D only?
- What are the data access constraints? EDC export only, or do you need to access the clinical database directly?
- Who is the statistical lead, and what level of QC is expected on the deliverables?
- Is validation documentation required for the tools you are building?
Key takeaway
Pharma R&D teams need data specialists who understand the regulatory context, can build reproducible pipelines, and communicate reliably about scope and timelines. That combination is rarer than technical skill alone, and it is what separates a good engagement from a difficult one.